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Results 
• A PBPK model for caffeine, theophylline, and ciprofloxacin was implemented using the Mathematica program.5, 9 
• Figures 1 and 2 show good correspondence between the model’s predictions (curves) with experimental data (points) 
for theophylline14 and ciprofloxacin1, 2, 3. 
• Many common beverages contain caffeine at relatively high doses.17 Figure 3 shows predicted plasma caffeine 
concentrations six hours after consuming a single serving of various beverages. 
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Abstract 
Dynamics of interactions between the drugs caffeine, 
theophylline, and ciprofloxacin are predicted using 
physiologically-based pharmacokinetic (PBPK) 
modeling. Pharmacokinetic means the model 
determines where the drugs are distributed in the body 
over time. Physiologically-based means the anatomy 
and physiology of the human body are reflected in the 
structure and functioning of the model. Multiple drugs 
can interact to increase or decrease their beneficial 
and/or undesired effects. This is important because 
some common substances, such as caffeine in coffee, 
soft drinks, and energy drinks, are actually drugs that 
affect the body. Ciprofloxacin is an inhibitor of caffeine 
and theophylline metabolism; such inhibition can lead 
to an overdose of caffeine and theophylline, and a 
reduced therapeutic effect for ciprofloxacin. PBPK 
modeling can be used by medical professionals to more 
precisely prescribe drug doses to achieve the desired 
therapeutic effects while minimizing the unwanted side 
effects by accounting for all drugs taken concurrently 
as well as lifestyle choices such as consumption of 
caffeinated beverages. 
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Example human 
(Charles Darwin) Example PBPK model9 
Figure 1: Concentration of theophylline in the venous system: model 
prediction (curve) and experimental data (points) for the same 
theophylline dose have the same color. 
Physiologically-based 
pharmacokinetic (PBPK) modeling8 
The block diagram (left) is an example of how a human 
(right) can be modeled: 
• Organs appear as compartments (blocks) connected 
by blood flow (arrows). 
• The model is described using differential equations. 
Pharmacokinetics is divided into several processes: 
• Absorption: Drugs can enter the body through 
various portals such as intravenous or oral routes. 
• Distribution: Drugs circulate through the body via 
blood flow, or accumulate in tissue. 
• Metabolism: Drugs may be changed or broken down 
into other substances by enzymes. 
• Elimination: Drugs or their metabolic products are 
eliminated from the body through various routes 
including the kidney (urine), liver, or lungs. 
Metabolism, drug interactions, and toxicity 
Metabolism: The diagram (right) shows pathways 
(arrows) by which caffeine, for example, is broken 
down in the liver by enzymes: 
• Caffeine is broken down into theophylline by the 
enzyme CYP1A2. 
• Theophylline is also broken down by CYP1A2. 
• Caffeine (top left) is a common psychoactive 
stimulant found in coffee, tea, soft drinks, and 
energy drinks. 
• Theophylline (middle left) is used to treat 
respiratory conditions such as asthma, infant 
apnea, and chronic obstructive pulmonary 
disease (COPD).  
• Ciprofloxacin (lower left) is an antimicrobial used 
to treat bacterial infections by inhibiting DNA 
and protein synthesis.7 It is also used by the 
military to protect against anthrax, a biological 
weapon. Ciprofloxacin slows the rate at which the 
body eliminates caffeine and theophylline.6 
  
Toxicity 
• Theophylline intoxication occurs at a plasma level of 20 mg/L; toxicity 
occurs at 60 mg/L for chronic overdoses and at 100 mg/L for an acute 
overdose, and can result in seizures, arrhythmias, and death.12, 16 
• For caffeine, 400 mg/day is a safe dose for healthy adults11, 200 
mg/day for pregnant women15, and 2.5 mg/day per kg body mass for 
children 11 (e.g., 80 mg/day for an average 10 year old 17). 
Figure 3: Predicted plasma concentrations of caffeine six hours after 
ingesting a single serving of various beverages (as a percentage of the 
recommended daily limit for healthy adults). Black bars denote 
recommended daily limits; blue bars denote beverages. 
• Ciprofloxacin inhibits CYP1A2. Mahr et al. provide experimental results for caffeine plasma levels when 
coadministered with ciprofloxacin.10 Fuhr et al. provide a value for KI : 0.18 mM.
4 The model predicts a 
poor match with experiment given this value for KI , and predicts a value of 1.4 μM for KI (data not shown). 
• Figure 4 shows the serum concentration of theophylline when administered alone (blue), and that 
theophylline administered with ciprofloxacin (red) leads to theophylline intoxication12 (exceeds black line) 
due to ciprofloxacin’s inhibition of CYP1A2, even when the doses of both drugs are consistent with 
therapeutic guidelines13.  
Figure 4: Concentration of theophylline in the venous system. The 
black line (20 mg/L) indicates the level for theophylline intoxication. 
The blue curve shows that theophylline given alone has a maximum 
concentration near the intoxication level, but given in combination 
with ciprofloxacin will exceed the intoxication level (both drugs given 
within dosage guidelines). 
Drug Interactions 
• A drug may affect the activity of another by altering its metabolism. 
• Ciprofloxacin inhibits CYP1A2 by binding to it.4 
• This slows down the metabolism of caffeine and theophylline which 
effectively increases their dose. 
• The dose of ciprofloxacin is also effectively decreased. 
• KI is the dissociation constant of the enzyme-inhibitor complex. 
Caffeine, theophylline, and ciprofloxacin 
Figure 2: Concentration of ciprofloxacin in the venous system: model 
prediction (curve) and experimental data (points) for the same 
ciprofloxacin dose have the same color. 
Conclusion and future work 
• Theophylline and ciprofloxacin, both prescribed within therapeutic guidelines, can, in combination, lead to 
theophylline intoxication due to ciprofloxacin’s inhibitory effect on theophylline metabolism. 
• The model predicts a value for KI for ciprofloxacin-CYP1A2 significantly different from the in vitro value 
determined by Fuhr et al. 
• Model development will continue with the inclusion of ciprofloxacin metabolism, leading to publication. 
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